ArticleBMC gastroenterology2021
Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.
Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Efficacy and safety of probiotics combined with bismuth-containing quadruple therapy forFrontiers in microbiology · 2025Pooled it
- The impact ofFrontiers in cellular and infection microbiology · 2025Pooled it
- Probiotic-based therapy as a new useful strategy for the treatment of patients with traumatic brain injury.BMC infectious diseases · 2024Pooled it
- The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.BMC infectious diseases · 2023Pooled it
- Study of the effect of LactobacillusFrontiers in immunology · 2023Trial
- Trial
- Effect of Probiotic-Assisted Eradication ofBioMed research international · 2022Trial
- Effects of Post-infection Supplementation with Lactiplantibacillus plantarum CRD7 and Lacticaseibacillus rhamnosus CRD11 on Helicobacter pylori Virulence Gene Expression in a Rat Model of Gastric Infection.Current microbiology · 2026Article
- Bile Acid Deconjugation and Anti-Helicobacter pylori Activity of Limosilactobacillus reuteri DSM 34531.Molecular nutrition & food research · 2026Article
- Hypothesizing the Biotherapeutic Potential of Nitrosotalea devanaterra: Targeting Ammonia Dependency to Disrupt Helicobacter pylori Survival Strategies in Gastritis.The Eurasian journal of medicine · 2026Article
- Characterization and Validation of the Antibacterial Activity ofFoods (Basel, Switzerland) · 2026Article
- Article
- The effects of postbiotics and glycyrrhetinic acid on immune response and inflammation-related genes during H. pylori eradication therapy.BMC microbiology · 2025Article
- Probiotics as Adjuvants to StandardMicroorganisms · 2025Review
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- Natural Products in the Management of Gastroesophageal Reflux Disease: Mechanisms, Efficacy, and Future Directions.Nutrients · 2025Review
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- Gut microbiota in gastric cancer: from pathogenesis to precision medicine.Frontiers in microbiology · 2025Review
- Recommendations and Adjuvant Therapies to Mitigate Clarithromycin-ResistantInfection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori (H. pylori) is the causative agent of stomach diseases such as duodenal ulcer and gastric cancer, in this regard incomplete eradication of this bacterium has become to a serious concern. Probiotics are a group of the beneficial bacteria which increase the cure rate of H. pylori infections through various mechanisms such as competitive inhibition, co-aggregation ability, enhancing mucus production, production of bacteriocins, and modulating immune response.
resultIn this study, according to the received articles, the anti-H. pylori activities of probiotics were reviewed. Based on studies, administration of standard antibiotic therapy combined with probiotics plays an important role in the effective treatment of H. pylori infection. According to the literature, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus rhamnosus GG, and Saccharomyces boulardii can effectively eradicate H. pylori infection. Our results showed that in addition to decrease gastrointestinal symptoms, probiotics can reduce the side effects of antibiotics (especially diarrhea) by altering the intestinal microbiome.
conclusionNevertheless, antagonist activities of probiotics are H. pylori strain-specific. In general, these bacteria can be used for therapeutic purposes such as adjuvant therapy, drug-delivery system, as well as enhancing immune system against H. pylori infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.